MIRA Pharmaceuticals, Inc.
MIRA
$0.8211
$0.01832.28%
| Weiss Ratings | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -22.54% | |||
| 30-Day Total Return | -19.50% | |||
| 60-Day Total Return | -34.83% | |||
| 90-Day Total Return | -37.32% | |||
| Year to Date Total Return | -28.60% | |||
| 1-Year Total Return | -20.28% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -83.98% | |||
| 52-Week Low % Change | 57.41% | |||
| Price | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.01 | |||
| 52-Week Low Price | $0.51 | |||
| 52-Week Low Price (Date) | Jul 03, 2024 | |||
| 52-Week High Price (Date) | Jul 22, 2024 | |||
| Valuation | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 13.50M | |||
| Enterprise Value | 10.67M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.48 | |||
| Earnings Per Share Growth | -41.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 6.05 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.82 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -1.33 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 16.56M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 786 432 9792 | |||
| Address | 1200 Brickell Avenue Miami, FL 32183 | |||
| Website | mirapharmaceuticals.com | |||
| Country | United States | |||
| Year Founded | 2020 | |||
| Profitability | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -127.59% | |||
| Return on Equity | -- | |||
| Income Statement | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -8.02M | |||
| Net Income (TTM) | -7.85M | |||
| Net Income Avl. to Common (TTM) | -7.85M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 58.54% | |||
| EPS Diluted (TTM) | -0.48 | |||
| EPS Diluted Growth (Q YOY) | 62.99% | |||
| Balance Sheet | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.83M | |||
| Cash Per Share (Q) | $0.17 | |||
| Total Current Assets (Q) | 2.89M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.20M | |||
| Current Ratio (Q) | 3.992 | |||
| Book Value Per Share (Q) | $0.13 | |||
| Total Assets (Q) | 2.92M | |||
| Total Current Liabilities (Q) | 723.30K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 723.30K | |||
| Total Common Equity (Q) | 2.20M | |||
| Cash Flow | MIRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 3.79M | |||
| Net Change in Cash (TTM) | -1.77M | |||
| Levered Free Cash Flow (TTM) | -3.59M | |||
| Cash from Operations (TTM) | -5.56M | |||
